Vincere Biosciences
PrivateLast Round
Grant
Nov 18, 2025
Total Funding Raised
$7.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Vincere Biosciences operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Grant round in November 2025.
Vincere Biosciences is a biotechnology company that develops small molecule therapeutics to treat age-related diseases, such as Parkinson's, by enhancing mitochondrial quality control.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vincere Biosciences Comparables
Compare Vincere Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Casma Therapeutics | 87% | |
| Mission Therapeutics | 86% | |
| OccamzRazor | 79% |
For institutional investors. Book with your work email.
Vincere Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 18, 2025 | ||||
| Strategic | May 22, 2025 | ||||
| Grant | Sep 25, 2023 | ||||
| Strategic | Jun 12, 2023 | ||||
| Grant | Jun 27, 2022 | ||||
Grant | Apr 13, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vincere Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Grant |
| NIH RADx | Grant |
| National Institute on Aging | Grant |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| National Institute on Aging | Grant |
| Draper Associates | Grant |
| National Institute of Neurological Disorders and Stroke | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 236% MoM, reaching 3.1K.
- Nov 18, 2025
Secured $5M in grant funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 14, 2026
Vincere Bio receives a $2.7M SBIR Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, on Sep 14th '26, with funding spanning two years to advance a USP30 inhibitor through IND-enabling studies for acute kidney injury.
For institutional investors. Book with your work email.
Vincere Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vincere Biosciences's valuation, stock price, and market status.
Is Vincere Biosciences a public or private company?
Vincere Biosciences is a private company.
What is the current stock price of Vincere Biosciences?
Vincere Biosciences is a private company, so its shares have no public market price. Caplight tracks Vincere Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vincere Biosciences worth (valuation)?
Valuation information for Vincere Biosciences is not publicly available.
Can I buy Vincere Biosciences stock?
Vincere Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vincere Biosciences's last funding round?
Vincere Biosciences's most recent funding round was Grant on November 18, 2025.
Who are the main investors in Vincere Biosciences?
Key investors in Vincere Biosciences include National Institute on Aging, The Michael J. Fox Foundation for Parkinson's Research, National Institute on Aging, National Institute of Neurological Disorders and Stroke.
Will Vincere Biosciences IPO soon?
No public IPO plans have been announced for Vincere Biosciences.
How can I track Vincere Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Vincere Biosciences's shares on secondary markets.